2.50
Hdl Handle:
http://hdl.handle.net/10755/165209
Category:
Abstract
Type:
Presentation
Title:
A NURSE CAN SAFELY DELIVER RITUXIMAB OVER 90 MINUTES
Author(s):
Corey, Peggy; Go, Ronald; Schaper, Ana
Author Details:
Peggy Corey, RN BSN OCN, Staff Nurse, Gundersen Lutheran Health System, La Crosse, Wisconsin, USA, email: prcorey@gundluth.org; Ronald Go, MD; Ana Schaper, RN, PhD
Abstract:
Implementation of evidence-based practice protocols for cancer treatment can benefit patients' quality of life and maximize utilization of available resources. Recently, three studies from academic centers suggest that rapid rituximab infusion (RRI), which reduces infusion time from 4 hours to 90 minutes in the treatment of non- Hodgkins lymphoma (NHL), is well tolerated and safe. However, cohorts in these studies were small and may not be reflective of the patient population treated in the community setting. Nurses, as patient advocates, need to be cautious of changes in treatment regimes, when based on limited evidence. For this project, the oncology nursing staff partnered with a physician to investigate the feasibility of RRI at a community-based cancer center. Patients, with NHL, were enrolled in this modified treatment program if they had received rituximab according to product monograph within the last 4 months, no prior grade 3 or 4 infusion related toxicities, no contra-indication to fluid infusion of 200 ml/hr, and an absolute lymphocyte count of <10,000. Patients were pre-medicated with acetaminophen and diphenhydramine. Rituximab was infused in 90 minutes (20% dose first 30 minutes; 80% dose next 60 minutes). Nurses monitored patients during and after infusion for toxicity as defined in common terminology for adverse events. Thirty-three patients were treated for total of 88 infusions (median 3). Clinical profile includes: median age of 69 years (range 32 to 88), 70% male, 67% stage III/IV disease. Chemotherapy regimens included: 33% CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone), 21% CVP (cyclophosphamide, vincristine, prednisone), 3% CF (cyclophosphamide, fludarabine), 6% CEP (cyclophosphamide, etoposide, prednisone), and 36% rituximab alone. No adverse events were observed for the 90-minute rituximab infusions. Rituximab infused over 90-minute was safe in the treatment of NHL and well tolerated in this community cohort. Both rituximab and chemotherapy were infused within 4 hours. The reduced infusion time allowed patients more control and flexibility in treatment scheduling, and more time away from the facility. In addition, shorter infusion times improved access in the chemotherapy suite.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleA NURSE CAN SAFELY DELIVER RITUXIMAB OVER 90 MINUTESen_GB
dc.contributor.authorCorey, Peggyen_US
dc.contributor.authorGo, Ronalden_US
dc.contributor.authorSchaper, Anaen_US
dc.author.detailsPeggy Corey, RN BSN OCN, Staff Nurse, Gundersen Lutheran Health System, La Crosse, Wisconsin, USA, email: prcorey@gundluth.org; Ronald Go, MD; Ana Schaper, RN, PhDen_US
dc.identifier.urihttp://hdl.handle.net/10755/165209-
dc.description.abstractImplementation of evidence-based practice protocols for cancer treatment can benefit patients' quality of life and maximize utilization of available resources. Recently, three studies from academic centers suggest that rapid rituximab infusion (RRI), which reduces infusion time from 4 hours to 90 minutes in the treatment of non- Hodgkins lymphoma (NHL), is well tolerated and safe. However, cohorts in these studies were small and may not be reflective of the patient population treated in the community setting. Nurses, as patient advocates, need to be cautious of changes in treatment regimes, when based on limited evidence. For this project, the oncology nursing staff partnered with a physician to investigate the feasibility of RRI at a community-based cancer center. Patients, with NHL, were enrolled in this modified treatment program if they had received rituximab according to product monograph within the last 4 months, no prior grade 3 or 4 infusion related toxicities, no contra-indication to fluid infusion of 200 ml/hr, and an absolute lymphocyte count of &lt;10,000. Patients were pre-medicated with acetaminophen and diphenhydramine. Rituximab was infused in 90 minutes (20% dose first 30 minutes; 80% dose next 60 minutes). Nurses monitored patients during and after infusion for toxicity as defined in common terminology for adverse events. Thirty-three patients were treated for total of 88 infusions (median 3). Clinical profile includes: median age of 69 years (range 32 to 88), 70% male, 67% stage III/IV disease. Chemotherapy regimens included: 33% CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone), 21% CVP (cyclophosphamide, vincristine, prednisone), 3% CF (cyclophosphamide, fludarabine), 6% CEP (cyclophosphamide, etoposide, prednisone), and 36% rituximab alone. No adverse events were observed for the 90-minute rituximab infusions. Rituximab infused over 90-minute was safe in the treatment of NHL and well tolerated in this community cohort. Both rituximab and chemotherapy were infused within 4 hours. The reduced infusion time allowed patients more control and flexibility in treatment scheduling, and more time away from the facility. In addition, shorter infusion times improved access in the chemotherapy suite.en_GB
dc.date.available2011-10-27T12:14:27Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:14:27Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.